Ophthalmic nano-bioconjugates: critical challenges and technological advances

Ophthalmic disease can cause permanent loss of vision and blindness. Easy-to-administer topical and systemic treatments are preferred for treating sight-threatening disorders. Typical ocular anatomy makes topical and systemic ophthalmic drug delivery challenging. Various novel nano-drug delivery app...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic delivery 2023-07, Vol.14 (7), p.419-441
Main Authors: Sanap, Sachin Nashik, Bisen, Amol Chhatrapati, Agrawal, Sristi, Kedar, Ashwini, Bhatta, Rabi Sankar
Format: Article
Language:English
Subjects:
clinical trials
nanocarriers
nanotechnology
ocular drug delivery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ophthalmic disease can cause permanent loss of vision and blindness. Easy-to-administer topical and systemic treatments are preferred for treating sight-threatening disorders. Typical ocular anatomy makes topical and systemic ophthalmic drug delivery challenging. Various novel nano-drug delivery approaches are developed to attain the desired bioavailability in the eye by increasing residence time and improved permeability across the cornea. The review focuses on novel methods that are biocompatible, safe and highly therapeutic. Novelty in nanocarrier design and modification can overcome their drawbacks and make them potential drug carriers for eye disorders in both the anterior and posterior eye segments. This review briefly discussed technologies, patented developments, and clinical trial data to support nanocarriers' use in ocular drug delivery.
ISSN:2041-5990
2041-6008
DOI:10.4155/tde-2023-0031